Biaromatic compounds which activate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof

1. A biaromatic compound having the structural formula (I):

in which:

R 1 is an alkyl radical having from 1 to 12 carbon atoms;

R 2 :

wherein R 8 is as defined below;

R 3 is a hydrogen atom, a halogen atom, an alkyl radical having from 1 to 12 carbon atoms, a hydroxyl radical, an alkoxy radical having from 1 to 7 carbon atoms, an aralkoxy radical, an aryloxy radical, a polyether radical, a nitro radical, or an amino radical optionally substituted with one or more alkyl radicals having from 1 to 12 carbon atoms, an aryl radical, an aralkyl radical, a heteroaryl radical or a heterocyclic radical;

R 4 is an alkyl radical having from 1 to 12 carbon atoms, an aryl radical, an aralkyl radical, a heteroaryl radical, a heterocyclic radical or a 9-fluorenylmethyl radical, a radical —(CH 2 ) a —(N—R 12 ) b —(CNR 15 ) c —R 6 , wherein R 6 , R 12 , R 15 , a, b and c are as defined below;

R 6 is a hydrogen atom, an alkyl radical having from 1 to 12 carbon atoms, an aryl radical, an aralkyl radical, a heteroaryl radical or a heterocyclic radical;

R 15 is a hydrogen atom, an alkyl radical having from 1 to 2 carbon atoms, an aryl radical, an aralkyl radical, a heteroaryl radical or a heterocyclic radical;

R 8 is a radical O—(CH 2 ) v —R 9 , an aralkoxy radical, an aryloxy radical, an aryl radical, an aralkyl radical, a heteroaryl radical, a heterocyclic radical, or the radical:

wherein R 9 , R′ and R″ are as defined below;

R′ is a heteroaryl radical or a heterocyclic radical;

R″ is a hydrogen atom, an alkyl radical having from 1 to 12 carbon atoms, an aryl radical, an aralkyl radical, optionally substituted with one or more halogen atoms, a heteroaryl radical, a heterocyclic radical or a radical (CH 2 ) v —R 9 , wherein R 9 and v are as defined below;

R 9 is an aryl, aralkyl or heteroaryl radical, a heterocyclic radical, a radical NH—CO—R 10 , a radical NH—CO—O—R 10 or C—R 10 R 11 or a radical N—R 10 —R 11 , wherein R 10 and R 11 are as defined below;

v has the values 1, 2 or 3;

R 10 is a hydrogen atom, an alkyl radical having from 1 to 12 carbon atoms, an aryl radical, an aralkyl radical, a heteroaryl radical or a heterocyclic radical;

R 11 is a hydrogen atom or an alkyl radical having from 1 to 3 carbon atoms;

R 14 is a halogen atom;

A is a radical having the following structure: —(CH 2 ) z —(N—R 12 ) y —(CO) x —(D) w or —(CH 2 ) z —(N—R 12 ) y —(CS) x —(D) w , wherein D, w, x, y, z and R 12 are as defined below;

D is an oxygen or sulfur atom, a radical —NR 13 or a CH 2 radical; R 13 is as defined below; w, x, y and z, which may be identical or difference, have the values 0 or 1, with the proviso that the sum x+y+z+w is greater than 2, and when x=0, then y or w=0;

R 12 and R 13 are each a hydrogen atom or an alkyl radical having from 1 to 12 carbon atoms,

and the optical and geometrical isomers and salts and mixtures thereof.

2. An alkali metal or alkaline-earth metal, zinc or organic amine salt of the biaromatic compound as defined by claim 1 .

3. The biaromatic compound as defined by claim 1 , wherein the alkyl radical having from 1 to 3 carbon atoms represented by R 11 is selected from the group consisting of methyl, ethyl and propyl radicals.

4. The biaromatic compound as defined by claim 1 , wherein the alkyl radical having from 1 to 12 carbon atoms represented by R 1 , R 3 , R 4 , R 6 , R 10 , R 12 , R 13 or R″ is selected from the group consisting of methyl, ethyl, isopropyl, butyl, tert-butyl, hexyl, heptyl, octyl, decyl and cyclohexyl radicals.

5. The biaromatic compound as defined by claim 1 , wherein the polvether radical represented by R 3 is selected from the group consisting of methoxymethoxy, ethoxymethoxy and methoxyethoxymethoxy radicals.

6. The biaromatic compound as defined by claim 1 , wherein the alkoxy radical having from 1 to 7 carbon atoms represented by R 3 is selected from the group consisting of methoxy, ethoxy, isopropyloxy, tert-butoxy, hexyloxy, benzyloxy and phenoxy radicals, which may optionally be substituted with an alkyl radical having from 1 to 12 carbon atoms.

7. The biaromatic compound as defined by claim 1 , wherein the aryl radical represented by R 3 , R 4 , R 6 , R 8 , R 9 , R 10 , R 15 or R″ is selected from the group consisting of phenyl, biphenyl, cinnamyl and naphthyl radicals, which may be mono- or disubstituted with a halogen atom, a CF 3 radical, an alkyl radical having from 1 to 12 carbon atoms, an alkoxy radical having from 1 to 7 carbon atoms, an aralkoxy radical or an aryloxy radical, a nitro function, a polyether radical, an aryl radical, a benzoyl radical, an alkyl ester group, a carboxylic acid, a hydroxyl radical optionally protected with an acetyl or benzoyl group or an amino function optionally protected with an acetyl or benzoyl group or optionally substituted with at least one alkyl radical having from 1 to 12 carbon atoms.

8. The biaromatic compound as defined by claim 1 , wherein the aralkyl radical represented by R 3 , R 4 , R 6 , R 8 , R 9 , R 10 , R 15 or R″ is selected from the group consisting of benzyl, phenethyl and 2-naphthylmethyl radicals, which may be mono- or disubstituted with a halogen atom, a CF 3 radical, an alkyl radical having from 1 to 12 carbon atoms, an alkoxy radical having from 1 to 7 carbon atoms, an aralkoxy radical or an aryloxy radical, a nitro function, a polyether radical, an aryl radical, a benzoyl radical, an alkyl ester group, a carboxylic acid, a hydroxyl radical optionally protected with an acetyl or benzoyl group or an amino function optionally protected with an acetyl or benzoyl group or optionally substituted with at least one alkyl radical having from 1 to 12 carbon atoms.

9. The biaromatic compound as defined by claim 1 , wherein the heteroaryl radical represented by R 3 , R 4 , R 6 , R 8 , R 9 , R 10 , R 15 , R′ or R″ is selected from the group consisting of pyridyl, furyl, thienyl, isoxazolyl, oxadiazolyl, oxazolyl, benzimidazolyl, indolyl and benzofuran radicals, optionally substituted with at least one halogen, an alkyl radical having from 1 to 12 carbon atoms, an alkoxy radical having from 1 to 7 carbon atoms, an aralkoxy radical or an aryloxy radical, an aryl radical, a nitro function, a polyether radical, an aryl radical, a benzoyl radical, an alkyl ester group, a carboxylic acid, a hydroxyl optionally protected with an acetyl or benzoyl group or an amino function optionally protected with an acetyl or benzoyl group or optionally substituted with at least one alkyl radical having from 1 to 12 carbon atoms.

10. The biaromatic compound as defined by claim 1 , wherein the heterocyclic radical represented by R 3 , R 4 , R 6 , R 8 , R 9 , R 10 , R 15 , R′ or R″ is selected from the group consisting of morpholino, piperidino, piperazino, 2-oxo-1-piperidyl and 2-oxo-1-pyrrolidinyl radicals, optionally substituted with at least one alkyl radical having from 1 to 12 carbon atoms, an alkoxy radical having from 1 to 7 carbon atoms, an aralkoxy radical or an aryloxy radical, an aryl radical, a nitro function, a polyether radical, an aryl radical, a benzoyl radical, an alkyl ester group, a carboxylic acid, a hydroxyl optionally protected with an acetyl or benzoyl group or an amino function optionally protected with an acetyl or benzoyl group or optionally substituted with at least one alkyl radical having from 1 to 12 carbon atoms.

11. The biaromatic compound as defined by claim 1 , selected from the group consisting of:

a. 1-[4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-yl]-3-heptyl-1-methylurea;

b. 1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-yl}-3-heptyl-1-methylurea;

c. 3-benzo[1,2,5]thiadiazol-4-yl-1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-yl}-1-methylurea;

d. 1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-yl}-1-methyl-3-thiophen-2-ylurea;

e. 2-butoxy-3-[3′-(3-heptyl-1-methylureido)biphenyl-4-yl]propionic acid;

f. 1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-yl}-1-methyl-3-(5-methyl-3-phenylisoxazol-4-yl)urea;

g. 2-benzoimidazol-1-yl-N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methylacetamide;

h. N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methyl-2-pyrid-4-ylthiazole-4-carboxylamide;

i. N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methyl-2-pyrid-4-ylthiazole-4-carboxylamide;

j. N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methyl-6-hydroxynaphthalene-2-carboxylamide;

k. N-[4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-ylmethyl]-N-methyl-6-hydroxynaphthalene-2-carboxylamide;

l. N-[4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-ylmethyl]-N-methylquinoxaline-6-carboxylamide;

m. N-[4′-(2-ethoxy-3-oxo-3-piperid-1-ylpropyl)biphenyl-3-ylmethyl]-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

n. N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

o. N-{4′-[2-ethoxy-3-oxo-3-(4-phenylpiperid-1-yl)propyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

p. N-{4′-[2-ethoxy-2-(3-methylbutylcarbamoyl)ethyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

q. N-{4′-[2-(cyclohexylmethylcarbamoyl)-2-ethoxyethyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

r. N-{4′-[2-ethoxy-2-(ethylpyrid-4-ylmethylcarbamoyl)ethyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

s. N-(4′-{2-[(2-dimethylaminoethyl)ethylcarbamoyl]-2-ethoxyethyl}biphenyl-3-ylmethyl)-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

t. N-{4′-[2-ethoxy-2-(2-piperid-1-ylethylcarbamoyl)ethyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

u. N-[4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-ylmethyl]-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

v. N-{4′-[2-(benzylmethylcarbamoyl)-2-ethoxyethyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

w. N-{4′-[2-ethoxy-3-(4-methylpiperazin-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

x. N-{4′-[2-(cyclohexylmethylcarbamoyl)-2-ethoxyethyl]biphenyl-3-ylmethyl}-N-methyl-6-(2-methoxyethoxymethoxy)naphthalene-2-carboxylamide;

y. 1-{4′-[2-cyclopropylmethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-yl}-3-hexyl-1-methylthiourea;

z. 1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-yl}-3-hexyl-1-methylthiourea;

aa. 1-[4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-yl]-3-hexyl-1-methylthiourea;

ab. [4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)-4-fluorobiphenyl-3-ylmethyl]methyloctanoylamide;

ac. 4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)-6-fluorobiphenyl-3-ylmethyl]methyloctanoylamide;

ad. 1-[4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)-6-fluorobiphenyl-3-yl]-3-heptyl-1-methylurea;

ae. 1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]-6-fluorobiphenyl-3-yl}-3-heptyl-1-methylurea;

af. 1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]-4-fluorobiphenyl-3-yl}-3-heptyl-1-methylurea;

ag. 1-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]-3′-fluorobiphenyl-3-yl}-3-heptyl-1-methylurea;

ah. 5-oxo-N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropy]biphenyl-3-ylmethyl}-N-methylhexanoylamide;

ai. {4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}methylhexanoylamide;

aj. 4-acetylamino-N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methylbutyramide;

ak. N-{4′-[2-cyclopropylmethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methyloctanoylamide;

al. N-[4′-(2-cyclopropylmethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-ylmethyl]-N-methyloctanoylamide;

am. N-[4′-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-ylmethyl]-N-methyloctanoylamide;

an. N-{4′-[2-ethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-ylmethyl}-N-methyloctanoylamide;

ao. N-[4′-(2-ethoxy-3-oxo-3-piperid-1-ylpropyl)biphenyl-3-ylmethyl]-N-methyloctanoylamide;

ap. 1-[4′-(2-ethoxy-3-oxo-3-piperid-1-ylpropyl)biphenyl-3-yl]-3-heptyl-1-methylurea;

aq. 1-[4′-(2-cyclopropylmethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-yl]-3-heptyl-1-methylurea;

ar. 1-[4′-(2-cyclopropylmethoxy-3-morpholin-4-yl-3-oxopropyl)biphenyl-3-yl]-1-methyl-3-pentylurea;

as. 1-[4′-(2-cyclopropylmethoxy-3-oxo-3-piperid-1-ylpropyl)biphenyl-3-yl]-1-methyl-3-pentylurea;

at. 1-[4′-(2-cyclopropylmethoxy-3-oxo-3-piperid-1-ylpropyl)biphenyl-3-yl]-3-heptyl-1-methylurea;

au. 1-{4′-[2-cyclopropylmethoxy-3-(4-methylpiperid-1-yl)-3-oxopropyl]biphenyl-3-yl}-3-heptyl-1-methylurea;

av. 3-heptyl-1-methyl-1-{4′-[3-(4-methylpiperid-1-yl)-3-oxo-2-propoxypropyl]biphenyl-3-yl}urea;

aw. 1-methyl-1-[4′-(3-oxo-3-piperid-1-yl-2-propoxypropyl)biphenyl-3-yl]-3-pentylurea; and

ax. 3-heptyl-1-methyl-1-[4′-(3-oxo-3-piperid-1-yl-2-propoxypropyl)biphenyl-3-yl]urea; and mixtures thereof.

12. The biaromatic compound as defined by claim 1 , having at least one of the following characteristics:

R 8 is a radical NR′R″;

A is the linking radical of structure —CH 2 N(R 12 )—CO or N(R 12 )—CO—(D) w in which w=0 or 1; and/or

R 4 is an alkyl, aryl or heteroaryl radical.

13. A pharmaceutical composition comprising a thus effective amount of the biaromatic compound as defined by claim 1 , formulated into a physiologically acceptable support therefor.

14. A cosmetic composition comprising a thus effective amount of the biaromatic compound as defined by claim 1 , formulated into a cosmetically acceptable support therefor.